Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$3.37 USD
+0.01 (0.15%)
Updated May 1, 2024 04:00 PM ET
After-Market: $3.36 -0.01 (-0.15%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Brokerage Reports
Aquestive Therapeutics, Inc. [AQST]
Reports for Purchase
Showing records 141 - 160 ( 397 total )
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Top and Bottom-Line Beat; All Eyes on Libervant; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Q2: Sights Set on Libervant Dec 23 PDUFA, Pipeline Updates in H2:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
FDA Accepts Libervant Resubmission for Review; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Libervant NDA Resubmission Accepted, PDUFA Set for December 23, 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L